Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Befetupitant is a neurokinin-1 (NK1) receptor antagonist (Ki = 1 nM).1 It inhibits GR73632-induced foot tapping in gerbils (ID50 = 0.2 mg/kg). Topical administration of befetupitant (0.4 or 1.6 mg/ml for four days) decreases hemangiogenesis and lymphangiogenesis but induces corneal opacity, stromal leukocyte infiltration, and corneal toxicity in a mouse model of corneal alkali burn.2
WARNING This product is not for human or veterinary use.
1. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-
2. NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 55(10), 6783-6794 (2014).